Partner Carl Hittinger was quoted in an April 4, 2023, article in the Daily Journal titled “FTC Blocks Illumina’s purchase of cancer biotech.” The piece focused on the Federal Trade Commission’s opposition to the purchase of Grail, Inc. by the San Diego biotechnology company Illumina Inc.
Hittinger told the publication that it is premature to draw too many conclusions from the decision because there have been so few cases challenging vertical mergers.
Read the article (subscription required).